Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07124000 · ClinicalTrials.gov registry record
DESTINY-PANTUMOUR04
A clinical trial of Head and Neck Cancer and Endometrial Cancer, sponsored by AstraZeneca.
- Recruiting
- Registry status
- 100
- Enrollment target
- 15
- Study locations
NCT07124000: Recruiting study of Head and Neck Cancer and Endometrial Cancer, sponsored by AstraZeneca.
NCT07124000 is a study of Head and Neck Cancer and Endometrial Cancer that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 100 participants, below the 260-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (62% lower). The trial reports 15 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07124000, a study of Head and Neck Cancer and Endometrial Cancer, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- 100 participants
- Enrollment target
- 15
- Study locations
Study Summary
This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options in a real-world setting in the US
Primary Outcome
rwRR is defined as the proportion of patients with a clinician assessment of complete or partial response while on T-DXd treatment
Conditions Studied
Interventions
- DRUG Trastuzumab deruxtecan
Study Locations (15)
Florida
- Research Site - Coral Springs
- Research Site - Fort Myers
- Research Site - Palm Harbor
North Carolina
- Research Site - Durham
- Research Site - Wilson
Ohio
- Research Site - Canton
- Research Site - Maumee
Alabama
- Research Site - Birmingham
Arizona
- Research Site - Casa Grande
California
- Research Site - San Diego
Colorado
- Research Site - Aurora
Illinois
- Research Site - O'Fallon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2025-09-18 |
| Est. Completion | 2028-03-30 |
What NCT07124000 shows while recruiting
NCT07124000 is an observational study that tracks outcomes without assigning an intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 260-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (62% lower).
The record links to 10 conditions, with Head and Neck Cancer appearing as the primary indexed condition, and to 1 intervention - of which Trastuzumab deruxtecan is the first listed.
NCT07124000 lists 15 locations in 11 states (Florida, North Carolina, Ohio).
Frequently Asked Questions
What is clinical trial NCT07124000 about?
NCT07124000 is a clinical study titled "DESTINY-PANTUMOUR04". This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options in a real-world ...
What is the current status of trial NCT07124000?
This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2025-09-18. Estimated completion is 2028-03-30.
What conditions does trial NCT07124000 study?
This clinical trial studies the following conditions: Head and Neck Cancer, Endometrial Cancer, Bladder Cancer, Cervical Cancer, Esophageal Cancer.
What interventions are being tested in trial NCT07124000?
The interventions under investigation include: Trastuzumab deruxtecan (DRUG).
Who is sponsoring clinical trial NCT07124000?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07124000 being conducted?
This trial has 15 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Head and Neck Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07124000's enrollment target sits among peer trials
100 82nd of 250 higher than 165 of 250 other Head and Neck Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Head and Neck Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
3D Specimen Maps for RT Planning
RECRUITING
-
Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer
RECRUITING · Phase 1
-
Prospective Evaluation of Pencil Beam Scanning Proton Therapy for Previously Irradiated Tumors
RECRUITING · NA
-
Improving Care for Rural Patients With Solid Tumors
RECRUITING · NA
-
Study of Non-invasive Acupuncture-like Transcutaneous Electrical Nerve Stimulation (Altens) to Help Alleviate Xerostomia After Radiation Therapy for Cancers of the Head and Neck
RECRUITING · NA
-
RAPA-201 Therapy of Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI